DURECT Corporation Presenting at the UBS Warburg Global Specialty Pharmaceuticals Conference

Download PDF:

CUPERTINO, Calif., Jun 5, 2002 /PRNewswire-FirstCall via COMTEX/ — DURECT
Corporation (Nasdaq: DRRX) announced today that it will present at the UBS
Warburg Global Specialty Pharmaceuticals Conference. The conference is taking
place June 5-6, 2002 at the Grand Hyatt New York. Thomas A. Schreck, Chief
Financial Officer will be presenting at the conference on Thursday, June 6, 2002
at 2:30 p.m. Eastern Time.

There will be a live webcast of the presentation from the Conference. The
webcast will be available on DURECT’s website at www.www.durect.com under the
Calendar of Events section of “Investor Relations.” The presentation will also
be available for replay on DURECT’s website for a period of 30 days after the

DURECT Corporation (www.www.durect.com) is pioneering the development and
commercialization of pharmaceutical systems for the treatment of chronic
debilitating diseases and enabling biotechnology-based pharmaceutical products.
DURECT’s goal is to deliver the right drug to the right site in the right amount
at the right time. DURECT’s lead product in development, the CHRONOGESIC(TM)
(sufentanil) Pain Therapy System, a 3-month product for the treatment of chronic
pain, completed a pilot phase III study in December 2001. DURECT owns three
proprietary drug delivery platform technologies, including the SABER(TM)
Delivery System (a patented and versatile depot injectable useful for protein
delivery), the MICRODUR(TM) Biodegradable Microparticulates (microspheres
injectable system) and the DURIN(TM) Biodegradable Implant (drug-loaded implant

NOTE: CHRONOGESIC(TM) is a trademark of DURECT Corporation. SABER(TM),
MICRODUR(TM) and DURIN(TM) are trademarks of Southern BioSystems, Inc., a wholly
owned subsidiary of DURECT Corporation. Other trademarks referred to belong to
their respective owners.

The statements in this press release regarding DURECT’s products in development,
expected product benefits, product development plans, future clinical trials,
potential product markets or projected future financial results are
forward-looking statements involving risks and uncertainties that can cause
actual results to differ materially from those in such forward-looking
statements. Potential risks and uncertainties include, but are not limited to,
DURECT’s ability to research, develop, manufacture and commercialize its
products, obtain product and manufacturing approvals from regulatory agencies,
manage its growth and expenses, finance its activities and operations, as well
as marketplace acceptance of DURECT’s products. Further information regarding
these and other risks is included in DURECT’s Annual Report on Form 10-K for the
fiscal year ended December 31, 2001 filed with the SEC on March 28, 2002, under
the heading “Factors that may affect future results,” and other periodic reports
filed with the SEC. CHRONOGESIC is under development by DURECT and has not been
submitted or approved for commercialization by the US Food and Drug
Administration or other health authorities.


Schond L. Greenway, Senior Director, Investor Relations and
Strategic Planning of DURECT Corporation, +1-408-777-1417, or


Copyright (C) 2002 PR Newswire. All rights reserved.

Scroll to Top